ANI Pharmaceuticals, Inc.
NASDAQ:ANIPDrug Manufacturers - Specialty & Generic
-$1.42 today
- Market cap
- $1.62B
- Beta
- 0.44
- P/E (TTM)
- 18.5
- EPS (TTM)
- $4.29
Volume 0.29M
Average 0.35M
ANIP Operating Cash Flow
Cash generated by the company's core business operations during the period.
ANI Pharmaceuticals, Inc.NASDAQ: ANIP
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $58.38M rose 66.8% year over year, behind the +158.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 92.2% from the prior quarter.
Context
- Operating cash flow amounted to 21.0% of revenue in FY2025, up 10.5 pp from a year earlier.
- Operating cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +66.8% toward the trailing-twelve-month pace of +158.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 185.23M USD
- Year-over-year change
- +189.3%
- 4-year CAGR
- +173.3%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 185.23M | +189.3% |
| FY2024 | 2024-12-31 | 64.02M | -46.2% |
| FY2023 | 2023-12-31 | 118.96M | +481.2% |
| FY2022 | 2022-12-31 | (31.2M) | -1039.3% |
| FY2021 | 2021-12-31 | 3.32M | — |
Operating Cash Flow vs competitors
How ANIP compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +158.4% is the 2nd highest of 10, against a peer median of +19.7%.
- Operating cash flow amounts to 22.6% of revenue for ANIP, versus a peer median of 12.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹30.11B INR | -48.8% | -1.3% | 9.1% | |
| LTM Jun 2026 | $2.33B USD | +12.9% | -8.3% | 15.8% | |
| LTM Jun 2026 | $1.9B USD | +36.5% | +1.2% | 11.0% | |
| LTM Jun 2026 | $1.8B USD | +19.7% | — | 16.6% | |
| LTM Mar 2026 | $331.04M USD | +66.8% | +38.4% | 41.6% | |
| LTM Mar 2026 | $208.61M USD | +158.4% | — | 22.6% | |
| LTM Jun 2026 | $200.78M USD | -42.8% | +73.5% | 6.4% | |
| LTM Mar 2026 | $168.88M USD | -12.6% | +20.5% | 23.4% | |
| LTM Mar 2026 | $36.59M USD | +59.0% | -20.7% | 12.1% | |
| LTM Mar 2026 | $17.38M USD | — | -79.1% | 12.9% | |
| LTM Mar 2026 | $15.2M USD | +626.1% | +195.2% | 5.7% | |
| Peer median (excluding ANIP) | — | +19.7% | +1.2% | 12.5% | |
Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.6M) | (47.9M) | 18.78M | (18.52M) | 78.34M |
| Depreciation & Amortization | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M |
| Deferred Income Tax | (16.75M) | (15.25M) | (11.74M) | (21.91M) | 14.24M |
| Stock-Based Compensation | 10.49M | 14.6M | 20.65M | 29.34M | 37.93M |
| Change in Working Capital | (84K) | (51.3M) | 24.86M | (11.19M) | (7.12M) |
| Accounts Receivables | (5.55M) | (36.91M) | 3.36M | (21.09M) | (58.53M) |
| Inventory | 3.22M | (23.63M) | (5.84M) | (21.29M) | (5.96M) |
| Accounts Payables | 10.17M | 5.04M | 7.55M | 479K | 15.16M |
| Other Working Capital | (7.93M) | 4.2M | 19.79M | 30.71M | 42.21M |
| Other Non-Cash Items | 5.02M | 8.99M | 6.62M | 18.56M | (29.57M) |
| Operating Cash Flow | 3.32M | (31.2M) | 118.96M | 64.02M | 185.23M |
| Capital Expenditures | (23.64M) | (16.46M) | (18.51M) | (16.95M) | (34.32M) |
| Acquisitions (Net) | (84.49M) | (33K) | 0 | (401.28M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (18.43M) | (6.83M) | (9.64M) | 12.8M | (20.49M) |
| Investing Cash Flow | (105.48M) | (15.74M) | (18.51M) | (404.72M) | (34.32M) |
| Debt Repayment | 99.02M | (3M) | (3M) | 345.22M | (10.16M) |
| Common Stock Issued | 69.58M | 0 | 80.56M | 0 | 13.6M |
| Common Stock Repurchased | (890K) | (1.96M) | (4.99M) | (10.96M) | (12.21M) |
| Dividends Paid | (190K) | (1.63M) | (1.63M) | (1.63M) | (1.16M) |
| Other Financing Activities | 2.07M | 1.46M | (3.5M) | (67.69M) | (26K) |
| Financing Cash Flow | 194.6M | (5.13M) | 67.44M | 264.95M | (9.94M) |
| Effect of Forex Changes | 0 | 0 | 0 | (470K) | (233K) |
| Net Change in Cash | 92.43M | (52.07M) | 167.89M | (76.23M) | 140.73M |
| Free Cash Flow | (20.32M) | (47.66M) | 100.45M | 47.06M | 150.9M |
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
Intrinsic Alpha fair value
Locked
Current Price
$71.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.